Table 1.
Characteristics of the patient tumors which were successfully established as PDX models
| PDX ID | ER | PR | HER2 | Age | Patient ethnicity | Clinical stage | Pathological grade |
Sample site |
|---|---|---|---|---|---|---|---|---|
| COH-GS1 | + | − | − | 71 | Hispanic | 2 | 3 | Breast |
| COH-GS2 | + | − | − | 63 | Hispanic | 3 | 3 | Breast |
| COH-SC7 | + | − | − | 63 | Caucasian | 4 | 2 | Chest wall |
| COH-GS3 | + | + | − | 52 | African-American | 4 | N/A | Brain |
| COH-SC1 | + | − | + | 34 | Caucasian | 2 | 2 | Breast |
| COH-SC31 | + | + | + | 72 | Caucasian | 4 | 3 | Chest wall |
| COH-SC48* | + | − | − | 53 | Caucasian | 2 | 3 | Breast |
| COH-SC49* | + | − | − | 67 | Caucasian | 2 | 3 | Breast |
| COH-GS4* | + | − | + | 37 | Caucasian | 4 | N/A | Brain |
*
2 of the ER+HER2− lines (COH-SC48 and COH-SC49) and 1 of the ER+HER2+ line (COH-GS4) were established after the RPPA analyses were performed. N/A; not applicable